Arnon Rosenthal, CEO of Alector LLC, told BioWorld that his firm is "opening a new modality, a new concept in therapeutics for Alzheimer's disease [AD]," and made a believer out of Abbvie Inc., which put down $205 million up front for the option rights to two candidates.